Project: Development of a potent bispecific antibody combination to treat colon cancer with reduced toxicity

Combine the proprietary technologies of the consortium members in a novel way to develop a combination product of bispecific antibodies that target and potently inhibit the HER family of receptor tyrosine kinases receptors (EGFR, HER2 and HER3) for the treatment of metastatic colorectal cancer. The project will deliver a lead candidate MCLA-125 with a manufacturing cell line, a manufacturing process, a clinical formulation and preclinical proof of concept in patient derived xenograft models.

Acronym	BiSECT (Reference Number: 9517)
Duration	15/02/2015 - 15/02/2017
Project Topic	Biological Sciences / Technologies
Network	Eurostars 2
Call	Eurostars Cut-Off 2

Project partner

Number	Name	Role	Country
20930	Merus BV	Coordinator	Netherlands
20931	Selexis SA	Partner	Switzerland